Tetraphase Pharmaceuticals, Inc. (TTPH) saw a big move last session, as the company’s shares fell by over 16% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for TTPH as the stock is now up around 8% in the past one-month time frame.
This slump shouldn’t be too much of a surprise to investors, as though the clinical-stage biopharmaceutical company has seen no negative revision in the past few weeks, its current year loss consensus has widened over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
TTPH currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Some better-ranked stocks in the Medical-Drugs industry include Endocyte, Inc. (ECYT), Synergy Pharmaceuticals, Inc. (SGYP) and Aerie Pharmaceuticals, Inc. (AERI). Among these stocks, Endocyte and Synergy carry a Zacks Rank #1 (Strong Buy) and Aerie holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
TETRAPHASE PHARMACEUTICALS INC (TTPH): Free Stock Analysis Report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
SYNERGY PHARMACEUTICALS DE (SGYP): Free Stock Analysis Report
AERIE PHARMACEUTICALS INC (AERI): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Health Care Industry